AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$SDGR

Schrödinger (SDGR) Q3 2026 Earnings Call Transcript

Schrödinger (SDGR) reported Q3 2026 earnings, highlighting 17% ACV growth and 19% total revenue increase. Key drivers included broader adoption in pharmaceuticals, new product introductions like Bunsen, and growth in biotech and material science sectors. The company raised full-year guidance for ACV and drug discovery revenue. Financials included $44.7M in ACV, $64.5M in total revenue, and a net loss of $38M. Hosted software licensing grew to 45% of software revenue.

Original reporting
finance.yahoo.com
Published Nov 5, 2026, 3:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 3:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Schrödinger (SDGR) Q3 2026 Earnings Call Transcript — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$SDGRBullishMed
01

Why it matters

Guidance raise reflects strong market adoption of its AI‑driven discovery platform across pharma and material science, likely supporting a bullish price move.

02

Market read

The earnings call provides fresh guidance that can shift investor expectations for SDGR and related AI‑driven biotech software stocks.

03

What to watch

Potential execution risk in transitioning customers to hosted licensing could temper revenue growth.

Relevance 7/10Novelty 7/10Timing: post‑earnings call today

Background

Schrödinger (SDGR) reported Q3 2026 results, highlighting 17% ACV growth, a milestone payment from its amylin program, and the launch of new AI product Bunsen.

Company-level read

Ticker impact

$SDGRBullishMedium confidence
Context

Schrödinger raised its full‑year 2026 ACV guidance to $222‑$232 million, indicating higher growth than previously forecast.

Expected impact

likely upward pressure as investors price in higher revenue expectations

Evidence & confidence

The new guidance is a primary disclosure with material revenue uplift; market typically reacts positively to upside guidance for a growth‑stage biotech software firm.

Market effects

Sector

Higher guidance may boost sentiment for AI‑enabled drug discovery and material science software providers.

Regional

Primarily affects US biotech/software investors; limited broader market effect.

Global

Shows growing adoption of computational chemistry platforms worldwide.

Counterpoint

What could challenge this read

If the guidance assumes continued high spend on AI tools, a slowdown in pharma budgets could pressure the stock.

Key entities

  • company
    Schrödinger

    AI‑driven molecular discovery software provider.

  • partner
    Takeda

    Received priority review for a co‑invented TYK2 inhibitor.

Read at source← All news

Also covered by

2 outlets

Related articles

$SDGRMed

Schrodinger Inc (SDGR) (Q3 2026) Earnings Call Highlights: Raised Guidance and Strong

Schrodinger Inc (SDGR) reported Q3 2026 earnings with a widened net loss of $38M, despite revenue growth. The company raised guidance, citing strong ACV and customer confidence in its technology. Revenue growth is impacted by a transition to hosted licensing. Bunsen, a new product, is in early access, and material science adoption lags behind pharma/biotech. Drug discovery revenue is milestone-dependent, with intensifying competition in AI-driven molecular discovery.

finance.yahoo.com
$SDGRMed

Schrödinger Reports Third Quarter 2026 Financial Results

Schrodinger, Inc. (SDGR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Schrödinger Reports Third Quarter 2026 Financial Results Third Quarter ACV of $45 Million, Representing 17% Growth Increases Full-Year 2026 ACV and Drug Discovery Revenue Guidance New York, November 4, 2026 – Schrödinger, Inc. (Nasdaq: SDGR) today announced financial

SEC EDGAR 8-K
$SDGRMed

SDGR Looks 19.2% Undervalued on GF Value™

Schrodinger Inc (NASDAQ: SDGR) launched Tectora, a biotech firm focused on immunology and inflammation, backed by a $55M Series A funding. SDGR's P/S ratio is 7.7x, below its 10.3x historical median, suggesting cautious growth expectations. Its GF Score™ is 72/100, indicating moderate fundamental strength with notable valuation and momentum but weak profitability. Insider activity shows $1.4M in selling over the past year, while institutional sentiment is mixed.

gurufocus.com